Astratinvest Launches Quant Long Short Fund, Aims to Raise Rs 400 Crore in 12 Months

Astratinvest has launched the Quant Long Short Fund, targeting to raise Rs 400 crore in 12 months. The fund aims to provide a systematic, data-driven approach to participating in the Indian equity markets. It is designed for sophisticated investors with a minimum investment threshold of Rs 1 crore. The fund is structured according to Sebi's private placement framework.

Astratinvest, a SEBI-registered Category III Alternative Investment Fund (AIF), has officially launched its flagship fund, the Astratinvest Quant Long Short Fund, with an ambitious target to raise Rs 400 crore in the next 12 months. The fund is designed to offer a systematic, data-driven approach to participating in India’s dynamic equity markets.

The fund is structured according to SEBI’s private placement framework and is intended for sophisticated investors with a minimum investment of Rs 1 crore as defined under AIF regulations. It distinguishes itself with a proprietary, multi-layered quantitative framework that dynamically adapts to market conditions while maintaining strict risk controls. The framework integrates four engines: MSQ (Market Strength Quantum), VSQ (Volatility Strength Quantum), S1+S2 Selection Engine, and RRQ (Risk Reward Quantum).

This systematic, data-driven approach offers a disciplined alternative to discretionary and factor-based quant strategies, aiming to deliver consistent alpha with strong downside protection in India’s evolving equity market. The launch of the fund aligns with a growing shift among Indian investors toward structured, data-driven investment strategies that prioritize consistency and risk management over speculation [1].

The fund’s launch comes at a time when the healthcare sector is witnessing significant growth, particularly in the single-specialty hospital segment. Asia Healthcare Holdings (AHH) has announced an investment of Rs 400 crore in Asian Institute of Nephrology and Urology (AINU), one of the largest single-speciality chains focused on uro-nephro care. The investment, which will occur over the next 4-5 years, is part of a larger plan to expand AINU’s hospital network by opening 13 new hospitals in Tier 2 cities [2].

The planned outlay of Rs 400 crore will take AHH’s full investment in the chain to Rs 1,000 crore since FY24, making it one of the largest investments in the single-speciality format in the urology-nephrology space. The market for single-specialty hospitals in India is expected to more-than-double to $31 billion in the next three-four years from the current $15 billion, according to a report from investment bank Avendus.

The launch of Astratinvest Quant Long Short Fund and AHH’s investment in AINU reflect the evolving investment landscape in India, where investors are increasingly looking for structured, data-driven strategies and opportunities in niche healthcare segments.

References:
[1] https://entrackr.com/snippets/astratinvest-launches-quant-long-short-fund-targeting-rs-400-cr-in-12-months-9652632
[2] https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/asia-healthcare-holdings-to-invest-rs-400-crore-in-asian-institute-of-nephrology-and-urology-to-double-hospital-network/articleshow/123241437.cms